Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The Impact of New SARS-CoV-2 Variants on Vaccine Breakthrough: A Pilot Study on Spreading Infection in the Communities

Mohamad Ammar Ayass, Jin Zhang, Kevin Zhu, Wanying Cao, Natalya Griko, Victor Pashkov, Jun Dai, Trivendra Tripathi, Lina Abi Mosleh
doi: https://doi.org/10.1101/2021.09.21.21263898
Mohamad Ammar Ayass
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mayass@ayassbioscience.com
Jin Zhang
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Zhu
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wanying Cao
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalya Griko
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Pashkov
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Dai
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trivendra Tripathi
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lina Abi Mosleh
Ayass Bioscience LLC, Frisco, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Coronavirus disease 2019 (COVID-19) vaccines are effective at helping protect against severe disease and death from variants; however, incident of breakthrough infection in vaccinated patients has been increased. Therefore, we aimed to assess the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) new variants of concern in the communities and investigate vaccine breakthrough cases on our laboratory (Ayass Bioscience LLC) confirmed detection of COVID-19 variants in Dallas-Fort Worth (DFW), Texas.

Methods Epidemiologic study has been performed at our laboratory. We studied the viral whole-genome sequence and genotyping analysis on 166 symptomatic cases of COVID-19 which were randomly selected from nasal swab positive cases assessed from June 1st to August 30th, 2021, by reverse transcription polymerase chain reaction (RT-PCR) cycle threshold (CT) values. COVID-19 variants were identified to be dominated by B.1.617.2 (89.2%) and followed by AY.3 (1.8%), B.1.1.7 (4.8%), a combination of B.1.526.1 and B.1.617.2 (3%), B.1.621 (0.6%), and P.2 (0.6%).

Result The CT values showed significant difference among the three age groups: <30 years, 31-60 years, and >60 years by one-way ANOVA (N1: F (2, 118) =4.96, p=0.009; N2: F (2, 118) =4.95, p=0.009). No significant difference was observed by symptom, status of immunization, or vaccine manufacturer. A two-way ANOVA was performed to examine the effect of gender and variant group (Delta and other variants) on the CT values. The analyses revealed a statistically significant interaction between the effect of gender and variant group (N1, F (1.117) = 3.906, p = 0.05; N2, F (1, 117) = 7.402, p = 0.008).

Conclusion Our study shows that Delta, the dominant variant of COVID-19, is spreading in the communities, and vaccine breakthrough cases occurred in the majority of Delta variant (91%) followed by AY.3 (5%), B.1.1.7 (2%) and 2% of the double variant of B.1.526.1 and B.1.617.2. The incidence of the breakthrough cases was not linked to a specific manufacturer. The CT value is likely to associate with age. This study also supports our laboratory’s ongoing efforts to sequence the SARS-CoV-2 virus from positive patient samples to identify the new viral variants and possible vaccine breakthrough mutations in the community.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

All work was sponsored by Ayass Bioscience LLC.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work was approved by the Salus institutional review board (ABS001_07_12_2021).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available on request from the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The Impact of New SARS-CoV-2 Variants on Vaccine Breakthrough: A Pilot Study on Spreading Infection in the Communities
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Impact of New SARS-CoV-2 Variants on Vaccine Breakthrough: A Pilot Study on Spreading Infection in the Communities
Mohamad Ammar Ayass, Jin Zhang, Kevin Zhu, Wanying Cao, Natalya Griko, Victor Pashkov, Jun Dai, Trivendra Tripathi, Lina Abi Mosleh
medRxiv 2021.09.21.21263898; doi: https://doi.org/10.1101/2021.09.21.21263898
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The Impact of New SARS-CoV-2 Variants on Vaccine Breakthrough: A Pilot Study on Spreading Infection in the Communities
Mohamad Ammar Ayass, Jin Zhang, Kevin Zhu, Wanying Cao, Natalya Griko, Victor Pashkov, Jun Dai, Trivendra Tripathi, Lina Abi Mosleh
medRxiv 2021.09.21.21263898; doi: https://doi.org/10.1101/2021.09.21.21263898

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1097)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9773)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1562)
  • Health Policy (736)
  • Health Systems and Quality Improvement (604)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11650)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4663)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)